Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA dips below year-ago levels
Q3 FY2026 EBITDA of $712.9M fell 47.4% year over year, behind the +4.3% change in trailing-twelve-month EBITDA. Sequentially, it fell 50.8% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- EBITDA amounted to 40.3% of revenue in FY2025, up 35.9 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 21 analysts of $7.22B (+48.4%) for the fiscal year ending Dec 2026, a slowdown from the +900.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $712.9M-50.8% QoQ
- Last fiscal yearDec 2025
- $4.87B+900.7% YoY
- LTMSep 2026
- $4.86B+4.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -47.4% | +21.3% | +68.7 pp |
| 1 year | +900.7% | +48.4% | -852.3 pp |
| 3-year CAGR | +3.1% | +24.6% | +21.5 pp |
| 5-year CAGR | +22.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 4.87B USD
- Year-over-year change
- +900.7%
- 4-year CAGR
- +13.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.87B | +900.7% |
| FY2024 | 2024-12-31 | 486.3M | -89.4% |
| FY2023 | 2023-12-31 | 4.61B | +3.8% |
| FY2022 | 2022-12-31 | 4.44B | +52.0% |
| FY2021 | 2021-12-31 | 2.92B | — |
EBITDA vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Sep 2026 EBITDA of $4.86B is the highest of the 11 companies compared; the peer median is -$429.07M.
- Its year-over-year change of +4.3% is the 6th highest of 11, against a peer median of +0.7%.
- EBITDA amounts to 37.4% of revenue for VRTX, versus a peer median of 44.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.86B | +4.3% | +3.1% | 37.4% | |
| LTM Jun 2026 | $1.15B | +773.6% | — | 24.0% | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Jun 2026 | -$63.18M | +83.2% | — | 40.5% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$611.26M | +5.0% | — | 85.7% | |
| LTM Sep 2026 | -$81.69B | -10676.6% | +29.2% | 8.0% | |
| Peer median (excluding VRTX) | -$429.07M | +0.7% | +29.2% | 44.9% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57B | 8.93B | 9.87B | 11.02B | 12.07B |
| Cost of Revenue | 904.2M | 1.08B | 1.26B | 1.53B | 1.81B |
| Gross Profit | 6.67B | 7.85B | 8.61B | 9.49B | 10.27B |
| Gross Margin | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% |
| Research & Development | 3.05B | 2.66B | 3.16B | 3.63B | 3.75B |
| Selling, General & Admin | 840.1M | 944.7M | 1.14B | 1.46B | 1.75B |
| Operating Expenses | 3.89B | 3.54B | 4.78B | 9.72B | 5.51B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| EBITDA | 2.92B | 4.44B | 4.61B | 486.3M | 4.87B |
| EBITDA Margin | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% |
| Operating Income | 2.78B | 4.31B | 3.83B | (232.9M) | 4.76B |
| Operating Margin | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% |
| Interest Income | 4.9M | 144.6M | 614.7M | 598.1M | 490.9M |
| Interest Expense | 61.5M | 54.8M | 44.1M | 30.6M | 13.3M |
| Other Income / Expenses | (51.7M) | (75M) | 547.8M | 481.4M | (117.5M) |
| Income Before Tax | 2.73B | 4.23B | 4.38B | 248.5M | 4.64B |
| Pre-Tax Margin | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% |
| Income Tax Expense | 388.3M | 910.4M | 760.2M | 784.1M | 690M |
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Net Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% |
| EPS (Basic) | 9.09 | 12.97 | 14.05 | (2.08) | 15.46 |
| EPS (Diluted) | 9.01 | 12.82 | 13.89 | (2.08) | 15.32 |
| Weighted Avg Shares | 257.7M | 256.1M | 257.7M | 257.5M | 255.7M |
| Weighted Avg Shares (Diluted) | 259.9M | 259.1M | 260.5M | 257.9M | 258M |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.